IP Library Granted Patent US 11,312,751
Granted Patent B2
US 11,312,751 · App. 17/231,526 · Granted Apr 26, 2022

MHC class I epitope delivering polypeptides

Inventors: Eric Poma (New York, NY); Erin Willert (Round Rock, TX)
Assignee: Molecular Templates, Inc.
C07K14/25C07K14/245C07K16/00C07K16/085C07K16/088C07K16/1063C07K16/286C07K16/2863C07K16/2866C07K16/2887C07K16/32C12N9/1077C12N9/2497C12N15/62C12Y204/02036C12Y302/02022A61K2039/6037C07K2319/04C07K2319/33C07K2319/40C07K2319/55Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,312,751
App. No.
17/231,526
Granted
Apr 26, 2022
Kind
B2
Abstract

The present invention is directed to T-cell epitope delivering polypeptides which deliver one or more CD8+ T-cell epitopes to the MHC class I presentation pathway of a cell, including toxin-derived polypeptides which comprise embedded T-cell epitopes and are de-immunized. The present invention provides cell-targeted, CD8+ T-cell epitope delivering molecules for the targeted delivery of cytotoxicity to certain cells, e.g., infected or malignant cells, for the targeted killing of specific cell types, and the treatment of a variety of diseases, disorders, and conditions, including cancers, immune disorders, and microbial infections. The present invention also provides methods of generating polypeptides capable of delivering one or more heterologous T-cell epitopes to the MHC class I presentation pathway, including polypeptides which are 1) B-cell and/or CD4+ T-cell de-immunized, 2) comprise embedded T-cell epitopes, and/or 3) comprises toxin effectors which retain toxin functions.

Claims (7)

1. A Shiga toxin effector polypeptide comprising an amino acid sequence having at least 90% identity to amino acids 1 to 251 of SEQ ID NO: 1;

wherein the amino acid sequence comprises at least four endogenous B-cell epitope regions, and comprises:

amino acid substitutions V54I, R55L, I57F, P59F, E60T, and E61L in SEQ ID NO: 1,

wherein the endogenous B-cell epitope regions are natively positioned in a wild-type Shiga toxin A Subunit within amino acid residues: 39-48 of SEQ ID NO:1; 94-115 of SEQ ID NO:1; 179-190 of SEQ ID NO:1; and 243-251 of SEQ ID NO:1; and

wherein the amino acid sequence comprises an asparagine at the amino acid residue corresponding to position 75 of SEQ ID NO: 1, a tyrosine at the amino acid residue corresponding to position 77 of SEQ ID NO: 1, a tyrosine at the amino acid residue corresponding to position 114 of SEQ ID NO: 1, a glutamate at the amino acid residue corresponding to position 167 of SEQ ID NO: 1, an arginine at the amino acid residue corresponding to position 170 of SEQ ID NO: 1, an arginine at the amino acid residue corresponding to position 176 of SEQ ID NO: 1, and a tryptophan at the amino acid residue corresponding to position 203 of SEQ ID NO: 1.

2. The Shiga toxin effector polypeptide according to claim 1 , wherein the amino acid sequence has at least 95% sequence identity to amino acids 1 to 251 of SEQ ID NO: 1.

3. The Shiga toxin effector polypeptide according to claim 1 , wherein the amino acid sequence has at least 95% sequence identity to SEQ ID NO: 16.

Assignments (2)
SECURITY INTEREST Recorded Jun 16, 2023
From: MOLECULAR TEMPLATES, INC.
To: ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE
Reel/Frame 063979/0709 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2021
From: POMA, ERIC; WILLERT, ERIN
To: MOLECULAR TEMPLATES, INC.
Reel/Frame 056204/0823 →
Continuity (5)
Continuation 16220568 · Dec 14, 2018
Continuation 15114474
Provisional Application 62049325 · Sep 11, 2014
Provisional Application 61932000 · Jan 27, 2014
Related Publication 20210253648A1 · Aug 19, 2021
Cited By (4)
US 12,227,567 US 12,281,166 US 12,497,458 US 12,637,495